News & Views

Adobestock 550344920

Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas

First-in-human trial is designed to determine recommended dose of IKS03, a CD19-directed antibody drug conjugate, for the subsequent dose-expansion. IKS03 is Iksuda’s second asset to begin clinical testing.

Adobestock 427889993

Iksuda to present growing ADC pipeline at AACR

Introduces the ProAlk payload series to address the growing challenge of ADC sequencing

ADC Foregraound & Background

Iksuda abstracts at AACR 2025

Iksuda’s abstracts have been scheduled for presentation in a Poster Session at the AACR Annual Meeting 2025 in Chicago, on Monday April 28 and have been published to the AACR Online Program Planner.

Adobestock 602058904

First patient dosed in Phase 1 Trial

Iksuda announces first patient dosed in Phase 1 trial of IKS014

Adobestock 427889993

Iksuda deepens clinical pipeline

Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences

Adobestock 550344920

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets

Sign up for more news

Thank you
*required field
*required field
*required field
I confirm that I have read the data protection and Privacy Policy and that I agree to the processing of my personal data